|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
VIT D REQUIREMENT IS INCREASED WITH CO-ADMINISTRATION
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
PARACETAMOL TOXICITY RISK ARE INCREASED BY TWO FOLD IF GIVEN WITH DRUGS THAT INDUCE LIVER MICROSOMAL ENZYMES
|
ACETAZOLAMIDE INCREASES THE RENAL EXCRETION OF THE DRUG
|
ALPHACALCIDOL REQUIREMENT IS INCREASED WHEN USED CONCOMITANTLY
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
PRIMIDONE ENHANCES THE DRUG METABOLISM, SO PLASMA LEVELS ARE REDUCED
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION OF DIAZEPAM AS AN ADJUNCT IN TREATING CONVULSIVE DISORDERS RESULTS IN POSSIBILITY OF AN INCREASE IN THE FREQUENCY AND/OR SEVERITY OF GRAND MAL SEIZURES WHICH MAY REQUIRE AN INCREASE IN THE DOSAGE OF STANDARD ANTICONVULSANT AGENT
|
CO-ADMINISTRATION MAY REDUCE SEIZURE CONTROL BY LOWERING THE PLASMA LEVELS OF ANTICONVULSANT; DOSAGE OF ANTICONVULSANT MAY NEED TO BE ADJUSTED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
CORTICOSTEROIDS PLASMA CONCENTRATION IS REDUCED & HENCE EFFICACY AS ITS METABOLISM IS INCREASED WITH CONCURRENT USE
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
ANTIEPILEPTICS MAY INCREASE CALCIUM REQUIREMENT, SO INCREASED DOSAGE IS TO BE GIVEN
|